logo
Contraceptives for poorest countries stuck in warehouses after US aid cuts

Contraceptives for poorest countries stuck in warehouses after US aid cuts

Yahoo21 hours ago

By Jennifer Rigby
LONDON (Reuters) -Contraceptives that could help prevent millions of unwanted pregnancies in some of the world's poorest countries are stuck in warehouses because of U.S. aid cuts and could be destroyed, two aid industry sources and one former government official said.
The stock, held in Belgium and Dubai, includes condoms, contraceptive implants, pills and intrauterine devices, together worth around $11 million, the sources told Reuters.
It has been stalled since the Trump administration started cutting foreign aid as part of its 'America First' policy in February, as the U.S. government no longer wants to donate the contraceptives or pay the costs for delivery, they said.
The U.S. Agency for International Development (USAID) has instead asked the contractor managing its health supply chain, Chemonics, to try to sell it, two of the sources said.
An internal USAID memo, sent in April, said a quantity of contraceptives was being kept in warehouses and they should be "immediately transferred to another entity to prevent waste or additional costs".
A senior U.S. State Department official told Reuters no decision had been made about the future of the contraceptives. They did not respond to questions about the reasons why the contraceptives were in storage or the impact of the U.S. aid cuts and delays.
A spokesperson for Chemonics said they were unable to comment on USAID's plans, but added that the company is working with clients to deliver life-saving aid globally and would continue to support the U.S. government's global health supply chain priorities.
The stock represents just under 20% of the supply of contraceptives bought annually by the U.S. for donation overseas, a former USAID official told Reuters.
Selling or donating the contraceptives has been challenging, according to the former USAID official, although talks are ongoing. Another option on the table is destroying it, at a cost of several hundred thousand dollars. As time goes on, shelf-lives will also become an issue, one of the sources said.
The sources told Reuters that one of the key delays is a lack of response from the U.S. government about what should be done with the stock.
It had been destined largely for vulnerable women in sub-Saharan Africa, including young girls who face higher health risks from early pregnancy as well as those fleeing conflict or who otherwise could not afford or access the contraceptives, the sources added.
The condoms also help stop the spread of HIV, the former USAID official said.
"We cannot dwell on an issue for too long; when urgency and clarity don't align, we have to move on," said Karen Hong, chief of UNFPA's supply chain. She said the agency is now working on Plan B to help fill critical supply gaps.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Who will be Trump's new Silicon Valley bestie?
Who will be Trump's new Silicon Valley bestie?

Business Insider

timean hour ago

  • Business Insider

Who will be Trump's new Silicon Valley bestie?

Mark Zuckerberg, Meta Platforms founder and CEO Zuckerberg was something of a MAGA stan earlier this year. Meta, his company, dropped $1 million on Trump's inauguration, and Zuck even co-hosted a black-tie soirée that night to honor the second-time president. Now, with Meta in the throes of a federal antitrust lawsuit, Zuckerberg may not be on Trump's good side. But the Meta CEO could be playing the long game here: He snapped up a $23 million, 15,000 square-foot DC mega mansion, establishing more of a presence in the capital. Zuck has also been on a bit of a rebrand journey, from a hoodie-wearing founder to a gold chain-wearing CEO with unapologetic swagger. Part of this transformation has included podcast appearances, like an episode with Trump-endorsing Joe Rogan in which Zuck talked about his "masculine energy" and his proclivity for bowhunting. Sam Altman, OpenAI cofounder and CEO Altman has also been circling the throne. First came Stargate: the $100 billion AI infrastructure plan between OpenAI, Oracle, and SoftBank, announced the day after Trump's inauguration. Then, in May, the OpenAI CEO joined Trump on a trip to Saudi Arabia while Altman was working on a massive deal to build one of the world's largest AI data centers in Abu Dhabi. This reportedly rattled Musk enough to tag along at the last minute, according to the Wall Street Journal. OpenAI was ultimately selected for the deal, which Musk allegedly attempted to derail, the Wall Street Journal reported. Jeff Bezos, Amazon founder and executive chairman, Washington Post owner, and Blue Origin founder Back in 2015, Bezos wanted to launch Trump into orbit after the at-the-time presidential candidate fired shots at Bezos on what was Twitter, now X, calling the Washington Post, which Bezos owns, a "tax shelter," Bezos responded that he'd use Blue Origin, a space company Bezos founded, to "#sendDonaldtospace." Times have certainly changed. In January, Bezos said he is "very optimistic" about the administration's space agenda. Behind the scenes, he has reportedly given Trump political advice, allegedly as early as the summer of 2024, according to Axios. There was a brief flare-up in April, though, after Amazon reportedly considered listing Trump's tariffs next to products' prices on the site, according to Punchbowl News. White House press secretary Karoline Leavitt called the plan a "hostile and political action." The idea, which was never implemented, was scrapped, and an Amazon spokesperson insisted it was only ever meant for its low-cost Haul store. If Trump does cancel Musk's SpaceX government contracts as he threatened to do, Bezos' Blue Origin, and rival to SpaceX, could stand to benefit. Blue Origin already has a $3 billion contract with NASA. Jensen Huang, Nvidia cofounder and CEO While Huang was notably missing from Trump's second inauguration in January, he did attend the Middle East trip in May. Nvidia is partnering with Oracle, SoftBank, and G42 on the OpenAI data center plans in the UAE. But Nvidia hasn't gotten off too easy: In April, Trump banned the chip maker from selling its most advanced chips, the H20, to China, a move that Nvidia says cost it $5.5 billion and reportedly prompted the company to modify the chip for China to circumvent US export controls. Sundar Pichai, Google CEO In April, a federal judge ruled that Google holds an illegal monopoly in some advertising technology markets. This is one of two major legal blows to Google in the past year: Back in August 2024, a federal judge ruled that Google violated antitrust law with its online search. If Google has to sell Chrome, Barclays told clients on Monday, Alphabet stock could fall 25%. This flurry of litigation — and potential divestment of the Chrome business — puts Pichai between a rock and a hard place. While the CEO was spotted with the rest of the technorati at Trump's inauguration, it's hard to say how he might cozy up to Trump, and whether friendly relations would do anything to remedy these rulings.

Why Viasat Stock Floated Higher Today
Why Viasat Stock Floated Higher Today

Yahoo

timean hour ago

  • Yahoo

Why Viasat Stock Floated Higher Today

It benefited from a growing dispute between President Trump and Elon Musk. If the latter loses federal government business for Starlink, Viasat could potentially poach such clients. 10 stocks we like better than Viasat › Satellite stocks were in vogue in late trading on Thursday, thanks to a rapidly escalating spat between two of the most high-profile individuals in the world. A beneficiary of this was Viasat (NASDAQ: VSAT), which ended up booking a 2.6% gain in its share price on the day. That made it an outperformer in light of the S&P 500 index's 0.5% decline. Earlier in the day, a social media war of words erupted between President Trump and former Department of Government Efficiency (DOGE) head Elon Musk. That occurred just after Musk, on his X (formerly Twitter) platform, leveled criticisms against Trump's One Big, Beautiful Bill currently making rather jagged progress through the Senate. In one of several responses on Trump's favored social media platform, Truth Social, the president made what can easily be taken as a direct and unambiguous threat to Musk's various businesses. He wrote that "The easiest way to save money in our budget, billions and billions of dollars, is to terminate Elon's governmental subsidies and contracts." Among Musk's businesses, which of course include Tesla, are SpaceX and Starlink. The latter company counts federal government agencies such as the Departments of Defense and Commerce as its clients. If such revenue sources were indeed to be cut off suddenly, the move would have quite a detrimental effect on Space X. Its loss would surely be rivals' gain; hence the interest in Viasat. The company provides satellite services that rival those of Starlink. Of course, so far there have been tough words but no action in regards to shutting off the federal taps that flow to Musk's business. Personally, I wouldn't trade Viasat or any potential beneficiary on rhetoric alone right now, but this is a rapidly developing story that's worth monitoring for anyone invested in satellite or space stocks presently. Before you buy stock in Viasat, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viasat wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy. Why Viasat Stock Floated Higher Today was originally published by The Motley Fool Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

HSBC Upgrades Dr. Reddy's Laboratories Limited (RDY) to Buy from Hold
HSBC Upgrades Dr. Reddy's Laboratories Limited (RDY) to Buy from Hold

Yahoo

time2 hours ago

  • Yahoo

HSBC Upgrades Dr. Reddy's Laboratories Limited (RDY) to Buy from Hold

On June 5, HSBC upgraded Dr. Reddy's Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from INR1,235, citing an optimistic outlook for the company in terms of earnings potential and solid market standing. A worker at a biopharmaceutical facility packaging an active pharmaceutical ingredient. HSBC's updated estimates for FY2026 to FY2028 take into account the shifting market tide for semaglutide and gRevlimid. The analysts are waiting for semaglutide to be introduced in Canada, Brazil, and India at the beginning of FY2027, which is a greater leap from their prior hypothesis of a launch only in Canada by Q4 of FY2026. The analysts revised their FY2026 sales figures for Dr. Reddy's Laboratories Limited (NYSE:RDY)'s gRevlimid, noting the growing competition. The adjustment includes a 5.1% decrease in the EPS estimate for FY2026, while the EPS forecast for FY2027 and FY2028 grew by 12% to 13%. According to HSBC analysts, the expected surge in semaglutide sales will strengthen Dr. Reddy's earnings. HSBC assigned a new price target for RDY's American Depositary Receipts (ADR) as well, raising it from $14.44 to $16.90. Dr. Reddy's Laboratories Limited (NYSE:RDY) is a global pharma company based in Hyderabad, India, that makes both branded and generic medicines for a wide range of health conditions. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. While we acknowledge the potential of RDY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store